PAREXEL Introduces its Connected Journey
BOSTON, June 19, 2017 – As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficient and effective, PAREXEL International Corporation, a global biopharmaceutical services provider, announced the launch of its Connected Journey™ of data-driven services. This new network, powered by PAREXEL® Analytics capabilities, combines PAREXEL’s technology and processes, to deliver critical intelligence supporting clinical development and commercialization.
PAREXEL’s Connected Journey consists of over 40 data-driven services. Its most recent, the ForeSite™ clinical trial methodology, integrates therapeutic area expertise, real-time analytics technology, and centralized oversight to predict site productivity. The solution enables sponsors to improve feasibility and site and country selection, as well as to more effectively engage and retain sites and patients.
“While drug companies have access to more data sources than ever before, they face challenges in generating and integrating meaningful insights that drive timely and actionable decisions,” said Mark A. Goldberg, MD, president and COO, PAREXEL. “Aggregating and leveraging the right data to drive value requires a broad range of services working together to generate insights across the entire drug development and commercialization spectrum. We believe PAREXEL’s global scale and broad technical expertise offer clients a uniquely integrated and comprehensive portfolio-delivered by a single provider.”
“The data resources to inform decision making are available, but to yield true value they must all be brought together,” said Xavier Flinois, president, PAREXEL Informatics. “PAREXEL’s Connected Journey moves from single solutions to the industry’s largest system of interrelated data-driven innovations. This model seamlessly connects data, technology, processes and multi-functional expertise, and is designed to foster close collaboration with all constituents.”
Contacts:
Media:
Dana Robie
Tel.: +1 781-434-4772
Email: Dana.Robie@PAREXEL.com
Kathryn McMahon, PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
Investors:
Ronald Aldridge
Tel.: +1-781-434-4753
Email: ron.aldridge@PAREXEL.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
